Special Issue "Neuromuscular Disorders: Current Gene and Cell Therapeutic Approaches"
Deadline for manuscript submissions: 30 September 2021.
Interests: RNA biology; regulatory RNA molecules; muscle regeneration, identification of genetic defects in inherited diseases
Special Issues and Collections in MDPI journals
Special Issue in Molecules: Towards Understanding the Mechanisms and Curing Of Muscular Dystrophy Diseases
Special Issue in Pharmaceuticals: Towards Understanding the Mechanisms and Curing Of Muscular Dystrophy Diseases
Special Issue in Pharmaceuticals: Chemically Modified Antisense Oligonucleotides: Promising Tools for the Therapy of Diseases
Special Issue in Molecules: Circulating RNA Molecules: A New Class of Potential Biomarkers
Special Issue in Medical Sciences: Biochemical and Genetic Insights in Obesity
Special Issue in Molecules: Biochemical and Genetic Insights in Obesity
Neuromuscular disorders are a heterogenic group of diseases affecting the muscular system or the peripheral nervous system. Some of these conditions are also associated with the central nervous system, such as amyotrophic lateral sclerosis (ALS). Neuromuscular disorders are predominantly characterized by progressive muscle weakness. Currently, no therapeutic treatments have been identified for any of these disorders. The high heterogeneity with respect to clinical severity, the cause of the disease, and the primary cell type that is affected (e.g., motor neurons, skeletal muscle, and Schwann cells) are considered the main challenges for the development of a successful therapeutic strategy for this group of disorders. However, in recent years, research into therapy development for neuromuscular disorders has made remarkable progress. Innovative therapeutic approaches have been applied to specific neuromuscular diseases with encouraging results.
This Special Issue will cover the recent progress in developing therapeutic and diagnostic strategies for neuromuscular disorders through a series of original research articles and reviews from experts in the field. Therapeutic approaches involving the use of nucleic acid oligonucleotides such as antisense oligonucleotides and miRNAs, biopharmaceutical compounds, genome editing, and different delivery tools including viral vectors and nanoparticles will be highlighted in this Special Issue.
Prof. Dr. Leonidas A. Phylactou
Dr. Andrie Koutsoulidou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Muscular dystrophies
- Motor neuron diseases
- Cell-based therapy
- Gene therapy
- Antisense oligonucleotides
- Pharmacological strategies
- Stem cells
- Viral vectors